$UPXI Income Statement | Understand Stock

$UPXI

$0.81 +$0.05 (6.45%) Close

$UPXI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of operations

In millions of USD; shares in millions, except per-share amounts

	FY2026 12 months to Jun 30, 2026	FY2025 12 months to Jun 30, 2025	FY2024 12 months to Jun 30, 2024	FY2023 12 months to Jun 30, 2023	FY2022 12 months to Jun 30, 2022
Revenue
Revenue
Digital asset revenue
Total revenue
Cost of revenue
Gross profit
Operating expenses
Sales and marketing
Distribution costs
General and administrative
Stock based compensation expense
Realized and unrealized (gain) loss on digital assets
Share-based compensation
Unrealized loss (gain) on digital assets
Realized loss on digital asset revenue conversion to USD
Realized loss on sale of digital assets
Stock-based compensation
Amortization of acquired intangible assets
Impairment on assets from manufacturing shut down
Impairment on acquired intangible assets
Gain on sale of property and equipment
Lease impairment, California facility
Depreciation
Impairment of long-lived asset - building
Loss on the sale / abandonment of assets in relocation
Lease impairment, Delray Beach facility
Impairment of intangible assets and goodwill
Lease Impairment (gain on settlement), Delray Beach facility
Total operating expenses
Loss from operations
Change in derivative liability
Other
Other expense, net
Other
(Loss) income before income tax
Interest (expense) income, net
Gain on sale of assets
Gain on SBA PPP loan forgiveness
Change in derivative liability
Settlement of cancelled lease
Interest expense, net
Gain on extinguishment of debt
Other expense, net
Loss on operations before income tax
Income tax benefit (expense)
Income tax benefit (expense), amount

Net loss from continuing operations
Infusionz and select assets
Interactive Offers
VitaMedica
E-core
Gain (loss) from the sale of total
Infusionz
Income (loss) income from discontinued operations
Net loss attributable to non-controlling interest
Deemed dividend related to the issuance of Series A Preferred Stock
Net (loss) income attributable to Upexi, Inc.
Net income (loss) attributable to Upexi, Inc.
Net loss
Income (loss) per share from continuing operations
(Loss) income per share from discontinued operations
Loss per share
Basic weighted average shares outstanding
Fully diluted weighted average shares outstanding

Comments